LEADER 03537nam 2200649Ia 450 001 9910457252903321 005 20200520144314.0 010 $a1-281-11983-0 010 $a9786611119836 010 $a0-08-054824-5 035 $a(CKB)1000000000357843 035 $a(EBL)305505 035 $a(OCoLC)162131368 035 $a(SSID)ssj0000098016 035 $a(PQKBManifestationID)11543273 035 $a(PQKBTitleCode)TC0000098016 035 $a(PQKBWorkID)10121606 035 $a(PQKB)10688063 035 $a(MiAaPQ)EBC305505 035 $a(Au-PeEL)EBL305505 035 $a(CaPaEBR)ebr10188620 035 $a(CaONFJC)MIL111983 035 $a(EXLCZ)991000000000357843 100 $a19930716d2007 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aAdvances in antiviral drug design$hVolume 5$b[electronic resource] /$feditor, E. De Clercq 210 $aGreenwich, CT ;$aLondon, England $cJai Press$d2007 215 $a1 online resource (265 p.) 225 0 $aAdvances in antiviral drug design ;$v5 300 $aDescription based upon print version of record. 311 $a0-444-52173-9 320 $aIncludes bibliographical references and index. 327 $aI. IntroductionII. Design; III. Synthesis; IV. Antiviral activity; Acknowledgements; References; Chapter 4. Synthesis and antiviral evaluation of broad spectrum, orally active analogs of cidofovir and other acyclic nucleoside phosphonates; I. Introduction; II. Synthesis of hexadecyloxypropyl and related esters of cidofovir; III. Antiviral evaluation and spectrum of activity; IV. Structure activity relationships; V. Cellular metabolism; VI. Oral pharmacokinetics and tissue distribution; VII. Antiviral activity in animal models of viral diseases 327 $aVIII. Alkoxyalkyl esters of (S)-HPMPA and other acyclic nucleoside phosphonatesIX. Conclusions; Acknowledgements; References; Chapter 5. CCR5 antagonistsCCR5 antagonists for the treatment ofHIV infection and AIDS; I. Introduction; II. Inhibition of HIV entry; III. CCR5 as a drug target; IV. The discovery of novel CCR5 antagonists; V. Molecular mechanisms; VI. Resistance to CCR5 antagonists in vitro and in the clinic; VII. Conclusions; References; Chapter 6. The medicinal chemistry of the DATADATA and DAPYDAPY series of HIV-1HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIsNNRTIs) 327 $aAbstractI. Introduction; II. The diaryltriazine (DATA) series; III. The diarylpyrimidine (DAPY) series; IV. Conclusion; Acknowledgements; References; Index 330 $aRegularly reviewing the ""state-of-the-art"" developments in the antiviral drug research field, this latest volume spans the conceptual design and chemical synthesis of new antiviral compounds. It discusses their structure-activity relationship, mechanism and targets of action, pharmacological behavior, antiviral activity spectrum, and therapeutic potential for clinical use. 410 0$aAdvances in Antiviral Drug Design 606 $aAntiviral agents 606 $aAnti-infective agents 608 $aElectronic books. 615 0$aAntiviral agents. 615 0$aAnti-infective agents. 676 $a616.9 676 $a616.9/25061/05 676 $a616.91061 701 $aDe Clercq$b Erik$066569 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910457252903321 996 $aAdvances in antiviral drug design$92167216 997 $aUNINA